EUCTR2004-000558-22-IT进行中（未招募）不适用
Assessment of the safety, efficacy, tolerability and pharmacokinetics of PegIntron plus Rebetol in pediatric patients with chronic hepatitis C.
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Informed consent must be obtained from subject’s parent or legal guardian prior to any study-related procedures and the subject must be able to adhere to the dose and visit schedule. According to local laws and/or IRB/IEC requirements, subjects may also need to provide written assent. 2. History of chronic hepatitis C as documented either by anti-HCV or HCV RNA positivity at least 6 months prior to Screening 1. 3. Subjects 3 through 17 years of age (inclusive) at time of Screening 2, of either gender. 4. Body weight =90 kg at the Screening 2 visit. In addition, subjects undergoing pharmacokinetic sampling must weigh =13 kg at the Screening 2 visit. 5. Plasma positive for HCV RNA by quantitative RT-PCR, as measured by the sponsor`s assay, during Screening 1 visit. 6. Results of a liver biopsy performed prior to entry to the study are required
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 10
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Serum ALT level >10 times the upper limit of normal within the 6 months prior to Screening 1 visit. 2. Any other cause for liver disease other than chronic hepatitis C. 3.Evidence of decompensated liver disease such as history or presence of ascites, bleeding varices or hepatic encephalopathy. 4. The most recent liver biopsy is normal, as determined by the local pathology report. 5. Prior treatment for chronic hepatitis C, including but not limited to antiviral or immunomodulatory product, any interferon product, or ribavirin, either as monotherapy or in combination. 6. Suspected hypersensitivity to any interferon product or ribavirin. 7. Known coinfection with either HIV or HBV. 8. Known immunodeficiency disorders requiring immunoglobulin therapy. 9. Known coagulopathies, including hemophilia, or anticoagulant use. 10. Known hemoglobinopathies. 11. Known G6PD deficiency. 12. Evidence of active or suspected malignancy, or a history of malignancy within the last 5 years. 13. Subjects with organ transplants.
研究者
相似试验
进行中（未招募）
1 期
Evaluation of the therapeutic potential of a low-dose therapy with the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus.Patients with systemic lupus erythematosus (SLE) and increased disease activity refractory to standard therapies.MedDRA version: 18.0Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 18.0Level: PTClassification code 10067657Term: Systemic lupus erythematosus disease activity index increasedSystem Organ Class: 10022891 - InvestigationsEUCTR2013-001599-40-DECharité - Universitätsmedizin Berlin12
已完成
1 期
Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus as prototypic autoimmune disease (PRO-IMMUN)M32.1Systemic lupus erythematosus with organ or system involvementDRKS00004858Charité - Universitätsmedizin Berlin10
进行中（未招募）
1 期
Assessment of the Safety, Efficacy, Tolerability and Pharmacokinetics of PEG-Intron Plus REBETOL for Pediatric Patients with Chronic Hepatitis CEUCTR2004-000558-22-ESSchering-Plough Research Insitute107
进行中（未招募）
1 期
Evaluation of the efficacy, safety and tolerability of alisporivir for the treatment of hospitalised patients with infections due to SARS-CoV-2 (COVID-19).The study population will consist of adults (18-80 years old) hospitalised for =48 hours prior to randomisation with a diagnosis of COVID-19 based on symptoms onset and SARS-CoV-2 RT-PCR test positive from nasopharyngeal swab. Patients with ARDS or patients requiring mechanical ventilation at screening or randomisation will be excludedMedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-002295-13-FRAssistance Publique - Hôpitaux Paris100
Unknown
3 期
Difluprednate 0.05% versus Prednisolone acetate 1% eye drops following phacoemulsification surgeryEye DiseasesPACTR202207762785564Suez Canal University Hospital800